CA Patent

CA2910760C — Targeting lipids

Assigned to Arbutus Biopharma Corp · Expires 2019-07-09 · 7y expired

What this patent protects

The present invention provides targeting lipids of structure (C1) L100 - linker - L101, where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or -CH2CH2(OCH2CH2)p O(CH2)q CH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositi…

USPTO Abstract

The present invention provides targeting lipids of structure (C1) L100 - linker - L101, where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or -CH2CH2(OCH2CH2)p O(CH2)q CH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

Drugs covered by this patent

Patent Metadata

Patent number
CA2910760C
Jurisdiction
CA
Classification
—
Expires
2019-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Arbutus Biopharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.